NK cell adoptive transfer in acute myeloid leukemia: a systematic review and meta-analysis - PubMed
6 hours ago
- #Immunotherapy
- #Acute myeloid leukemia
- #Natural killer cells
- NK cell adoptive transfer is a promising immunotherapy for acute myeloid leukemia (AML) with low graft-versus-host disease risk.
- In relapsed/refractory AML, a meta-analysis of 11 studies showed a pooled response rate of 35%, with higher responses linked to enhanced NK activation strategies.
- For high-risk AML patients in remission but ineligible for stem cell transplant, 1-year disease-free survival was 26%, improving to 82% in low/intermediate-risk cases.
- Combining NK transfer with haploidentical stem cell transplantation resulted in a 1-year disease-free survival of 40%, albeit with high heterogeneity among studies.
- The therapy is generally safe with mild toxicities, low severe events, and improved persistence through multiple infusions or CIML-NK approaches.